RUNX1 and acute myeloid leukemia: A recent systematic profiling of chromatin signatures and gene mutations in AML patient samples has identified two distinct subtypes, in which a RUNX1-mutant subgroup appears to represent more late-stage leukemic cells with a better prognosis [65].